**Tidal Volume Lower than 6 ml/kg Enhances LungProtection Role of Extracorporeal Carbon Dioxide Removal**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available http://hdl.handle.net/2318/103813       since

*Published version:*

DOI:10.1097/ALN.0b013e3181b764d2

*Terms of use:*

Open Access

(Article begins on next page)

25 April 2024

# Tidal volume lower than six milliliter/kilogram enhances lung protection: Role of extracorporeal carbon dioxide removal

**Pier Paolo Terragni, MD** [*], **Lorenzo Del Sorbo, MD** [*], **Luciana Mascia, MD, PhD** [*],

**Rosario Urbino, MD** [*], **Erica L. Martin, PhD** [*], **Alberto Birocco, MD** [#],

**Chiara Faggiano, MD** [#], **Michael Quintel, MD** [§], **Luciano Gattinoni, MD** [§],

**and V. Marco Ranieri, MD** [§]

***Running head***: Carbon dioxide removal and protective ventilation

***Summary Statement***: Tidal volume lower than 6 milliliter/kilogram minimizes *ventilator induced lung injury* when plateau pressure ranges between 28 and 30 cmH$_2$O; extracorporeal carbon dioxide removal may manage consequent respiratory acidosis

[*] Assistant Professor of Medicine; [#] Resident in Anesthesia; [§] Professor of Anesthesia

**PPT**, **LDS**, **LM**, **RU**, **ELM**, **AB**, **CF** and **VMR**: Dipartimento di Anestesiologia e Medicina degli Stati Critici, Università di Torino, Ospedale S. Giovanni Battista-Molinette, Torino, Italy; **MQ**: Department of Anesthesiology, University of Gottingen, Gottingen, Germany; **LG**: Istituto di Anestesia e Rianimazione, Fondazione IRCCS – Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena" di Milano; Università degli Studi di Milano, Italy

Institution to which the work should be attributed and address for correspondence and reprint requests:  V. Marco Ranieri, MD Università di Torino, Dipartimento di Anestesiologia e di

Medicina degli Stati Critici, Ospedale S. Giovanni Battista-Molinette, Corso Dogliotti 14,

10126 Torino Tel:  39-011-633-4001; Fax: 39-011-696-0448; e-mail:  marco.ranieri@unito.it

# Abstract

*Background:* Tidal hyperinflation may occur in patients with acute respiratory distress syndrome that ventilated with a tidal volume ($V_T$) of 6 ml/kg of predicted body weight develop a plateau pressure ($P_{PLAT}$) of $28 \leq P_{PLAT} \leq 30$ cmH$_2$O. We verified if $V_T < 6$ ml/kg may enhance lung protection and that consequent respiratory acidosis may be managed by extracorporeal carbon dioxide removal.

*Methods:* $P_{PLAT}$, lung morphology computed tomography, and pulmonary inflammatory cytokines (broncho-alveolar lavage) were assessed in 32 patients ventilated with a $V_T$ of 6 ml/kg. Data are provided as mean ± standard deviation or median and interquartile (25 and 75 percentile) range. In patients with $28 \leq P_{PLAT} \leq 30$ cmH$_2$O (N=10), $V_T$ was reduced from 6.3±0.2 to 4.2±0.3 ml/kg and $P_{PLAT}$ decreased from 29.1±1.2 to 25.0±1.2 cmH$_2$O (P<0.001); consequent respiratory acidosis (PaCO$_2$ from 48.4±8.7 to 73.6±11.1 mmHg and pH from 7.36±0.03 to 7.20±0.02; P<0.001) was managed by extracorporeal carbon dioxide removal. Lung function, morphology and pulmonary inflammatory cytokines were also assessed after 72 hours.

*Results:* Extracorporeal assist normalized PaCO$_2$ (50.4±8.2 mmHg) and pH (7.32±0.03) and allowed use of $V_T$ lower than 6 ml/Kg for 144 [84,168] hours. The improvement of morphological markers of lung protection and the reduction of pulmonary cytokines concentration (P<0.01) were observed after 72 hours of ventilation with $V_T$ lower than 6 ml/Kg. No "patient related" complications were observed.

***Conclusions:*** $V_T$ lower than 6 ml/Kg enhanced lung protection. Respiratory acidosis consequent to low $V_T$ ventilation was safely and efficiently managed by extracorporeal carbon dioxide removal.

# Introduction

Limitation of tidal volume ($V_T$) to 6 mL/kg predicted body weight (PBW) and of end-inspiratory plateau pressure ($P_{PLAT}$) to a maximum of 30 cmH$_2$O represents the gold standard for mechanical ventilation of patients with acute respiratory distress syndrome (ARDS)[1,2]. However, recent studies found that (a) tidal hyperinflation may occur in some patients despite limiting $V_T$ to 6 mL/kg and $P_{PLAT}$ to 30 cmH$_2$O[3]; (b) ARDS patients may benefit from $V_T$ reduction even if they already have $P_{PLAT}$ < 30 cmH$_2$O[4].

Extracorporeal assist separating carbon dioxide removal from oxygen uptake has been proposed by Gattinoni and coworkers[5]. With this technique, carbon dioxide is removed by a pump driven veno-venous bypass while oxygenation is accomplished by high levels of positive end-expiratory pressure (PEEP) and three-five sighs every minute[5]. Although effective[5], negative results of a clinical trial[6], the extensive amount of required resources[7], and the high incidence of side effects[8] restricted the use of extracorporeal carbon dioxide removal as "rescue" therapy for the most severe case of ARDS[9].

To reduce complexity, expenses, and side effects of extracorporeal lung assistance, Pesenti and coworkers proposed the concept of removing "*only a portion of* carbon dioxide *production*" to allow less traumatic ventilator settings[10]. The present study set up to examine the hypothesis that a modified renal replacement circuit incorporating a neonatal membrane lung coupled in series with a hemofilter may safely remove the amount of carbon dioxide sufficient to buffer the respiratory acidosis associated to $V_T$ lower than 6 mL/kg and allow more protective ventilatory settings.

# Material and Methods

## PATIENT SELECTION

Patients admitted from July 2006 to September 2007 in the intensive care units of the S. Giovanni Battista-Molinette hospital (University of Turin, Turin Italy) were enrolled. Inclusion criteria were: age $\geq$ 18 years; diagnosis of ARDS[11]. Exclusion criteria were: > 3 days since they met ARDS criteria; pulmonary artery occlusion pressure > 18 mmHg; history of ventricular fibrillation, tachyarrhythmia, unstable angina or myocardial infarction within preceding month; chronic obstructive pulmonary disease; chest wall abnormalities; chest tube; abdominal distension; body mass index > 30; pregnancy; intracranial abnormality[12].

The institutional review board (Comitato Etico Interaziendale, Regione Piemonte, Turin), approved the study. As the patients at study entry were incompetent, consent was delayed. The family was informed of the study (although not required) and the study was performed. Written permission for using collected data was hence obtained from the patient (if competent) or from the family (in case of death or if the patient remained incompetent)[13].

## STUDY PROTOCOL

All consecutive patients that met inclusion and exclusion criteria were treated for 72 hours according to the "*ARDSNet*" strategy[2]. A detailed description of the protocol can be found in the *supplemental digital content*.

After 72 hours of ventilation according to the "*ARDSNet*" strategy[2], $P_{PLAT}$ was recorded for a period of one hour with an half–second inspiratory pause keeping ventilator setting constant and abolishing spontaneous respiratory muscles activity by (*a*) reaching a Ramsay score of sedation 5 (midazolam up to 0.15 mg/kg/hour, morphine up to 0.03 mg/kg/hour, and

propofol up to 2 mg/kg/hr)[14]; (***b***) increasing, if required before measurements, doses of midazolam (up to 10 mg/h) and/or propofol (150mg/h increments every 10 min)[15,16].

In the patients that had 25<$P_{PLAT}$<28 cmH$_2$O, the "*ARDSNet*" strategy[2] was maintained at least for the following 72 hours (**Figure 1**). In patients that had 28 ≤$P_{PLAT}$≤ 30 cmH$_2$O the following strategy was implemented and maintained for at least the following 72 hours (**Figure 1**): (***a***) $V_T$ was stepwise reduced (1 ml/kg of PBW every four hours) until $P_{PLAT}$ 25<$P_{PLAT}$<28 cmH$_2$O; (***b***) to manage the re-absorbtion atelectasis that may occur during mechanical ventilation with low $V_T$ [17,18], PEEP-FiO$_2$ combination was set according to the "higher PEEP" arm of the ALVEOLI study [12]; (***c***) respiratory rate was increased up to 40 breaths/min and bicarbonate infused up to 20 mEq/hr; (***d***) if pH was ≤ 7.25, extracorporeal carbon dioxide removal was initiated using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 0.33 m$^2$ (**Decap**®, Hemodec, Salerno, Italy)[19] (**LOWER "*ARDSNet*"/CARBON DIOXIDE REMOVAL**) (**Figure 2**).

Femoral vein was accessed via a double lumen catheter (14 F; Arrow International Inc. Reading PA) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow was driven through the circuit by a roller non-occlusive low flow pump (0-500 ml/min) through a membrane lung (Polystan SAFE, Maquet, Rastatt, Germany) that was connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 L/min. Exiting the membrane lung, blood was driven to a hemofilter (Medica D200, Medolla, Italy). The resulting plasmatic water was re-circulated through the membrane lung by a peristaltic pump (0-155 ml/min).

The membrane lung and the hemofilter were coupled in series in order to: (a) increase the pressure inside the membrane lung by adding the downstream resistance exerted by the

hemofilter and therefore reduce the risk of air bubble formation[20]; (b) minimize the need for heparin by diluting the blood entering the membrane lung by re-circulating the plasmatic water separated by the hemofilter[21]; (c) enhance the performance of the extracorporeal device extracting the carbon dioxide dissolved in the plasmatic water separated by the hemofilter and re-circulated through the membrane lung[22] (**Figure 2**).

Pressure developed by the roller pump (arterial pressure) was measured and limited to 120-150 mmHg.  Re-infusion pressure (venous pressure), and the pressure gradient across the membrane lung and the hemofilter (drop pressure: pre-membrane lung pressure–venous pressure) were also measured. Detectors of leaks and bubbles were inserted within the circuit. The circuit, including the membrane lung was primed with saline with a volume that ranged between 140 and 160 ml.

A starting dose of heparin (80 IU/kg bolus and 18 IU/kg/h infusion) was delivered using a syringe pump included in the system. Heparin continuous infusion was hence titrated to maintain the activated partial thromboplastine time ratio to approximately 1.5.

After 72 hours of **LOWER "*ARDSNet*"/CARBON DIOXIDE REMOVAL** strategy, the following "weaning trial" was conducted once a day:  flow through the circuit was set to the lowest value (50 ml/min), $V_T$ was increased to 6 ml/kg PBW and PEEP-$FiO_2$ combination was set according to the conventional "*ARDSNet*" strategy[2].  If with these ventilator settings $P_{PLAT}$ remained for more that 3 hours < than 28 $cmH_2O$, extracorporeal carbon dioxide removal was interrupted and conventional "*ARDSNet*" ventilatory strategy re-established.

## MEASUREMENTS

Underlying disease responsible for ARDS, clinical status and laboratory data on admission (the worst value within 24 hours after admission) were recorded for calculation of the Simplified Acute Physiology Score II[23].

*Clinical variables*

Clinical variables [$P_{PLAT}$, $V_T$, respiratory rate, PEEP, minute ventilation, $PaO_2/FIO_2$ ratio, $PaCO_2$, pH, continuous cardiac output (Vigileo system, Edwards LifeScience, Irvine, CA), heparin doses, and activated partial thromboplastine time ratio] were prospectively collected at the following scheduled times: after 72 hours of ventilation according to the conventional "*ARDSNet*" strategy and, in those patients that had $28 \leq P_{PLAT} \leq 30$ cmH$_2$O, after lowering $V_T$ and before initiating carbon dioxide removal (***baseline***), and after 60-90 minutes (***T₁.₅***), 24 (***T₂₄***), 48 (***T₄₈***) and 72 (***T₇₂***) hours after initiation of carbon dioxide removal.  Blood flow during carbon dioxide removal was recorded at ***T₁.₅, T₂₄ T₄₈ T₇₂***.

Potential complications during the procedure were prospectively classified as "mechanical" (cannula problems, membrane lung failure, clots in the circuit, air in the circuit, pump malfunction, tubing rupture, catheter displacement, system leaks) and "patient related" [*vein perforation*, *significant bleeding* (i.e. any bleeding event that required the administration of 1 unit of packed red cells), *hemodynamic instability* (i.e. 80-90 mmHg increase or a 30-40 mmHg decrease in systolic blood pressure relative to the baseline value or need for inotropic drugs for at least two hours to maintain systolic blood pressure higher than 85 mmHg  or electrocardiogram evidence of ischemia or significant ventricular arrhythmias) *ischemic/gangrenous bowel, pneumothorax, renal complications* (i.e. occurrence after

initiation of carbon dioxide removal of creatinine > 1.5 mg/dL), *infectious complications* (i.e.

occurrence after initiation of carbon dioxide removal of culture proven new infection),

*metabolic* (i.e. occurrence after initiation of carbon dioxide removal of glucose ≥ 240 mg/dL or

hyperbilirubinemia), *thromboembolic complications* (i.e. occurrence after initiation of deep

venous thrombosis or pulmonary embolus), and *neurologic complications* (i.e. occurrence after

initiation of carbon dioxide removal of cerebral infarction, or clinical seizure, or cerebral

hemorrhage or cerebral edema] and their occurrence recorded during the period the **LOWER**

**"*ARDSNet*"/CARBON DIOXIDE REMOVAL** strategy was recorded.

*Lung morphology*

A pulmonary CT scan of the whole lung was performed in all patients after study

enrollment. The CT scan was repeated after approx 72 hours of ventilation with the **LOWER**

**"*ARDSNet*"/CARBON DIOXIDE REMOVAL** strategy in those patients that had $28 \leq P_{PLAT} \leq 30$

$cmH_2O$, and after approx 72 hours of ventilation with the conventional "*ARDSNet*" strategy in

some of the patients that had $25 < P_{PLAT} < 28$ $cmH_2O$ (**Figure 1**). A detailed description of the

methods used can be found in the *supplemental digital content*[3].

Weight and volume of the entire lungs and of the *non-aerated, poorly aerated, normally*

*aerated*, and *hyperinflated* compartments were assessed[13,24]. "***Protected tidal inflation***" and

"***tidal hyperinflation***" were defined as the volume of the *normally aerated* and *hyperinflated*

compartment at end-inspiration minus the volume of the *normally aerated* and *hyperinflated*

compartment at end-expiration, respectively. "***Tidal recruitment* of the *non-aerated***

**compartment**" was defined as the volume of the *non-aerated* compartment at end-expiration

minus the volume at end-inspiration. All were expressed as % of the total tidal inflation-related

change in CT lung volume[3,24].

*Pulmonary inflammatory response*

A broncho-alveolar lavage was performed in all patients after study enrollment[25]. The broncho-alveolar lavage was repeated after approx 72 hours of ventilation with the **LOWER** "***ARDSNet***"/**CARBON DIOXIDE REMOVAL** strategy in the patients that had $28 \leq P_{PLAT} \leq 30$ cm $H_2O$, and after approx further 72 hours of ventilation with the conventional "*ARDSNet*" strategy in some of the patients that had $25 < P_{PLAT} < 28$ cmH$_2$O (**Figure 1**). Interleukin 6 (IL-6), interleukin 8 (IL-8) and interleukin 1 (IL-1b) and IL-1 receptor antagonist (IL-1Ra) were measured. A detailed description of the methods used can be found in the *supplemental digital content*[25].

## STATISTICAL ANALYSIS

Data are expressed as mean ± standard deviation of the mean or median and inter-quartile (25 and 75 percentile) range as appropriate. To evaluate differences between the two groups, the Fisher's exact test for categorical variables, and the t-test with unequal variance for continuous variables were used. Data at different time during carbon dioxide removal were compared by analysis of variance (ANOVA) for repeated measures using a Bonferroni correction. If significant ($P \leq 0.05$), the values at ***baseline***, $T_{1.5}$, $T_{24}$, $T_{48}$, and $T_{72}$ were compared with those obtained after 72 hours ventilation according to the "*ARDSNet*" strategy using a paired t-test as modified by Dunnett. All tests were two tailed. Analysis was carried out using the SPSS software package (SPSS Inc. Chicago, IL).

# Results

Of the 32 patients that matched study criteria, 22 patients had $25 < P_{PLAT} < 28$ cmH$_2$O and 10 patients had a $28 \leq P_{PLAT} \leq 30$ cmH$_2$O. Patients characteristics are shown in **Table 1**. Age, gender, Simplified Acute Physiology Score II and underlying diseases responsible for ARDS did not differ between the two groups; PaO$_2$/FiO$_2$ ratio was lower in patients with $28 \leq P_{PLAT} \leq 30$ cmH$_2$O than in patients with $25 < P_{PLAT} < 28$ cmH$_2$O (P<0.01).

Lungs were heavier and the extent of the *hyperinflated*, *non-aerated* and *poorly aerated* CT lung compartments were larger, and of the *normally aerate*d compartment smaller in patients with $28 \leq P_{PLAT} \leq 30$ cmH$_2$O than in patient with $25 < P_{PLAT} < 28$ cmH$_2$O (all P<0.001) (**Table 2**). "***Protected tidal inflation***" was smaller and "***tidal hyperinflation***" was larger in patients that had $28 \leq P_{PLAT} \leq 30$ cmH$_2$O than in the patients that had $25 < P_{PLAT} < 28$ cmH$_2$O ($19 \pm 6$ vs. $81 \pm 6$ and $67 \pm 5$ vs. $11 \pm 4$ % of the total tidal-inflation associated change in CT lung compartments, respectively; P<0.01). "***Tidal recruitment* of the *poorly aerated* compartment**" did not differ between the two groups of patients.

In the patients that had $28 \leq P_{PLAT} \leq 30$ cmH$_2$O, V$_T$ was decreased from $6.3 \pm 0.2$ to $4.2 \pm 0.3$ ml/kg PBW and P$_{PLAT}$ decreased from $29.1 \pm 1.2$ to $25.0 \pm 1.2$ cmH$_2$O (all P<0.001). Despite the increase in respiratory rate (from $31.2 \pm 2.3$ to $37.0 \pm 1.9$ b/min; P<0.001) and bicarbonate infusion ($20.2 \pm 0.8$ mEq/hr), the reduction in minute ventilation (from $12.03 \pm 2.77$ to $9.03 \pm 1.18$ L/min; P<0.001) increased PaCO$_2$ (from $48.4 \pm 8.7$ to $73.6 \pm 11.1$ mmHg; P<0.001) and decreased pH (from $7.36 \pm 0.03$ to $7.20 \pm 0.02$; P<0.001). The increase in PEEP (from $12.1 \pm 2.5$ cmH$_2$O to $15.2 \pm 0.8$ cmH$_2$O, P < 0.001) attenuated the reduction in PaO$_2$/FiO$_2$ (from $135 \pm 30$ to

124±29; P < 0.01) associated to the lowering of $V_T$ (**Figure 3**).  All patients met pH criteria for

carbon dioxide removal and were therefore connected to the veno-venous bypass.

Sixty-ninety minutes of veno-venous bypass decreased $PaCO_2$ to 50.4±8.2 mmHg and

increased arterial pH to 7.32±0.03 (P<0.001).  After 72 hours of extracorporeal support, $PaCO_2$

and arterial pH were 47.2±8.6 mmHg and 7.38±0.04, respectively (P<0.001) (**Figure 4**).  The

extracorporeal veno-venous carbon dioxide removal device was used for 144 hours [84,168].

The pump-driven blood flow through the circuit ranged between 191-422 ml/min (5-10 % of

cardiac output) (**Table 3**).  Heparin infusion ranging between 3 and 19 IU/Kg was needed to

maintain activated partial thromboplastine time ratio between 1.1 and 1.7 (**Table 3**).

No "patient related" complications were observed.  "Mechanical" complications are

reported in **Table 4**.  In three cases, the 14 F double lumen catheter had to be replaced by two 8

F simple-lumen catheters (one for each femoral vein) due to recirculation issues (two cases)

and catheter kinking (one case). None of the reported malfunctions impaired patient's status

during the procedure. The membrane clotting observed in three patients did not result in

additional transfusion.  The **LOWER "*ARDSNet*"/CARBON DIOXIDE REMOVAL** strategy did not

require any increase in nursing resources.  A technician with expertise in the **Decap**® system

was present (9 a.m.- 5 p.m.) during the treatment of the first five patients.

Average lung density histograms of tidal changes in CT lung compartments in patients

that during the "*ARDSNet*" strategy had 28≤$P_{PLAT}$≤30 cmH₂O are shown at study entry (**Figure**

**5A,** *left*) and after 72 hours of **LOWER "*ARDSNet*"/CARBON DIOXIDE REMOVAL** strategy

(**Figure 5A,** *right*). Ventilation with the **LOWER "*ARDSNet*"/CARBON DIOXIDE REMOVAL** was

associated to: (***a***) the reduction of lung weight and of the extent of the *hyperinflated, non-*

*aerated* and *poorly aerated* CT lung compartments and the increase of the extent of the *normally aerate*d lung compartments (P<0.001) (**Table 2**); (**b**) the increase of "***protected tidal inflation***" (from 19±6 to 86±8 % of the total tidal-inflation associated change in CT lung compartments; P<0.01); (**c**) the reduction of "***tidal hyperinflation***" (from 67±5 to 5±4 % of the total tidal-inflation associated change in CT lung compartments; P<0.01); (**d**) a significant improvement of $PaO_2/FiO_2$ (from 136±30 to 221±56; P<0.001) (**Figure 3**). Same data for the patients that during the "*ARDSNet*" strategy had 25<$P_{PLAT}$<28 $cmH_2O$ are shown at study entry (**Figure 5B, *left***). In 12 of the 22 patients CT scan were obtained after further 72 hours of conventional "*ARDSNet*" strategy (**Figure 5B, *right***); these data were retrospectively obtained using CT scan performed for other studies or for clinical reasons. Relative to study entry, further 72 hours of conventional "*ARDSNet*" strategy were also associated to the reduction of lung weight and of the extent of the *hyperinflated, non-aerated* and *poorly aerated* CT lung compartments and the increase of the extent of the *normally aerate*d lung compartments (P<0.05) (**Table 2**) with no changes in amount of "***protected tidal inflation***" and "***tidal hyperinflation***" (**Figure 5B, *left***); a significant improvement of $PaO_2/FiO_2$ (from 185±60 to 301±42; P<0.001) was also observed.

Pulmonary concentration of inflammatory cytokines at study entry were lower (P = 0.001) in patients that during the "*ARDSNet*" strategy had 25<$P_{PLAT}$<28 $cmH_2O$ than in patients that had 28≤$P_{PLAT}$≤30 $cmH_2O$. In the former, further 72 hours of conventional "***ARDSNet***" strategy did not modify concentration of pulmonary inflammatory cytokines (data were retrospectively obtained in 15 of the 22 patients using broncho-alveolar lavage performed for other studies). In the latter, the use of the **LOWER "*ARDSNet*"/CARBON DIOXIDE**

**REMOVAL** strategy was associated to a significantly reduced concentration of pulmonary inflammatory cytokines (P = 0.001) (**Figure 6**). Broncho-alveolar lavage procedure did not cause complications in any of the studied patients.

# Discussion

Use of $V_T$ lower than 6 ml/kg PBW in patients that during "*ARDSNet*" ventilation had $28 \leq P_{PLAT} \leq 30$ cmH$_2$O was associated to a significant reduction of inflammatory and morphological markers of ventilator induced lung injury. Respiratory acidosis consequent to further $V_T$ reduction was effectively and safely corrected using a modified renal replacement device incorporating a membrane lung.

These results support the use of extracorporeal carbon dioxide removal as a tool that, integrated with conventional ventilation, allows more protective ventilator settings[9]. However, these data can only be used as proof of principle since: (***a***) the confounding effect of time on the observed improvement of physiological, radiographic and inflammatory parameters before and after 72 hours of **LOWER "*ARDSNet*"/CARBON DIOXIDE REMOVAL** strategy can't be ruled out since we don't have a control group of patients with $28 \leq P_{PLAT} \leq 30$ cmH$_2$O who received usual care without **LOWER "*ARDSNet*"/CARBON DIOXIDE REMOVAL**. Moreover, the study design prevents us for knowing what the respective effect of decreasing $V_T$, increasing PEEP and applying carbon dioxide removal. (***b***) We could not assess weather the observed substantial decrease in PaCO$_2$ with the limited blood flow was exclusively related to the device used in the study since measurements of extracorporeal carbon dioxide transfer and of total body carbon dioxide production were not performed. (***c***) Studies in experimental models suggest that un-buffered respiratory acidosis may reduce ventilator induced lung injury[26]. It is therefore possible that physiological, morphological and inflammatory variables would have improved as much or more if we reduced $V_T$ and $P_{PLAT}$ without carbon dioxide removal. (***d***) None of the patients that during "*ARDSNet*" ventilation had $28 \leq P_{PLAT} \leq 30$ cmH$_2$O was able to reach the

target $P_{PLAT}$ values (25-28 cm $H_2O$) with the increase in respiratory rate and bicarbonate infusion. This may be because in three patients $V_T$ was reduced more than required since in these patients $P_{PLAT}$ before initiating extracorporeal carbon dioxide removal was 24.2, 23.3 and 24.1 $cmH_2O$, values that are lower that the target $P_{PLAT}$. Moreover tris-hydroxymethyl aminomethane, a non- carbon dioxide generating buffers that was recently showed to efficiently manage respiratory acidosis[27,28] was not used in the present study.

Gattinoni and coworkers hypothesized that "to rest the lung", oxygenation *via* mechanical ventilation could be dissociated from decarboxylation *via* extracorporeal carbon dioxide removal[5]. In Gattinoni's study, mechanical ventilation was limited to apneic oxygenation and to 3-5 sighs every minute with peak inspiratory pressure not higher than 35-45 $cmH_2O$; PEEP ranged between 15 and 25 $cmH_2O$. carbon dioxide removal was performed using a pump driven veno-venous bypass allowing blood flow to pass through two membrane lungs (9 m2 total membrane surface area). Extracorporeal blood flow was progressively raised from 200 to 300 mL/min to the selected maintenance flow (20-30 % of cardiac output). Although the observed mortality rate was lower than expected, several episodes of severe bleeding were reported[5]. A subsequent randomized clinical trial did not confirm these data[6]. Concerns have been therefore raised regarding the standard use of extracorporeal support[6,29] because of the high incidence of serious complications such as hemorrhage, hemolysis, and neurological impairments[8]. Extracorporeal carbon dioxide removal has been therefore restricted to the sickest patients in whom all other treatments have failed [30] and to centers with large expertise[31].

Retrospective evaluation of the "*ARDSnet*" database suggested that $V_T$ reduction would

have improved outcome even in patients that already had $P_{PLAT} < 30$ cm $H_2O$[4]. Moreover, physiological[32] and morphological[3] evidences of *tidal hyperinflation* have been described in patients in whom the "*ARDSNet*" strategy resulted in $28 \leq P_{PLAT} \leq 30$ cm$H_2O$. These data have therefore challenged the view of extracorporeal support only as "rescue therapy"[33,34,35] and have generated the hypothesis that extracorporeal carbon dioxide removal may be incorporated in a lung protective strategy to allow further reduction of $V_T$ and $P_{PLAT}$[9].

The concept originally developed by Pesenti and coworkers of removing "*only a portion of* carbon dioxide *production*"[10] has been recently implemented in new devices that may reduce side effects, complexity and costs of extracorporeal carbon dioxide removal[19,33]. Bein and coworkers recently reported the use of a pump-less extracorporeal device in ARDS patients[34]. Retrospective analysis of 90 patients demonstrated that using this device was possible to obtain physiologic values of $PaCO_2$ (31-42 mmHg) and pH (7.38-7.50) despite ventilation with low $V_T$ (320–470 ml). However, the authors reported a complication rate of 24% including limb ischemia, compartment syndrome, and intracranial hemorrhage. In addition, continuous intravenous infusion of norepinephrine was needed to maintain the pressure gradient between arterial and venous blood.

In the present study, carbon dioxide removal was performed through a dedicated pump-driven extracorporeal venous-venous circuit with a neonatal membrane lung and a hemofilter coupled in series (**Figure 2**). The main elements that characterize and differentiate this system are: (*a*) a blood flow lower than the one used in standard carbon dioxide removal [191-422 ml/min (5-10 % of cardiac output) vs. 1.5-2.0 L/min (20-30 % of cardiac output][5,6,36]; (*b*) a small neonatal membrane lung (0.33 m$^2$) instead of two large adult membrane lung (3-4.5 m$^2$ each)[5,6,36]; (*c*) the use of 14 F double lumen catheters instead of large 21-28 F double or single

lumen catheters[9]; (*d*) a priming volume smaller than currently used [(140-160 ml vs. 1500-1800 mL)[37]]; (*e*) a relatively small infusion rate of heparin (3-19 IU/Kg) and less hypo-coagulation than used in previous studies (activated partial thromboplastine time ratio of 1.1-1.7 vs. 2.0-2.5)[5,6].

Seventy-two hours of use of this extracorporeal bypass was associated to a 33.6±6.3 % reduction of $PaCO_2$ (from 73.6±11.1 to 48.5±6.3 mmHg, P <0.001) sufficient to normalize arterial pH (from 7.20±0.02 to 7.38±0.04, P <0.001) while ventilating patients with $V_T$ ranging between 167 and 340 ml (3.7-4.6 ml/Kg PBW) and minute ventilation ranging between 8.1 and 11.9 L/min. No adverse events in terms of vein perforation, significant bleeding, hemodynamic instability, ischemic/gangrenous bowel, pneumothorax, and renal, infectious, metabolic, thromboembolic, and neurological complications were observed during the 141±69 hours in which the device was in clinical use. However, since the level of blood flow required to normalize arterial pH (up to 422 ml/hr) was relatively high for a circuit like the one used in the present study[38], the 14 F double lumen catheter had to be replaced in three cases by two 8 F simple-lumen catheters (one for each femoral vein).

Re-absorption atelectasis may occur during mechanical ventilation with low $V_T$ depending on the $FiO_2$, the regional ventilation/perfusion ratios and the end-expiratory lung volume[17]. In a recent study, Dembinsky and coworkers randomized animals with ARDS to be ventilated for 24 hours with a $V_T$ of 3 mL/kg or with a $V_T$ of 6 mL/kg; consequent respiratory acidosis was managed in the former group removing carbon dioxide via a pump-less system[18]. The study showed that despite a significant reduction of $P_{PLAT}$, organ function and organ injury assessment did not reveal significant improvements when compared with conventional

strategy. On the contrary, pulmonary gas exchange was impaired because of increased pulmonary ventilation/perfusion mismatch. In the present study, after 72 hours of **LOWER "*ARDSNet*"/CARBON DIOXIDE REMOVAL** strategy we observed (*a*) the reduction of lung weight and of the extent of the *non-aerated* and *poorly aerated*; (*b*) the increase of the extent of the *normally aerate*d CT lung compartments lung (**Table 2**), (*c*) a significant improvement of $PaO_2/FiO_2$ (from 136±30 to 221±56; P<0.001) (**Figure 5**). These differences may be explained by the fact that while in Dembinsky's study, PEEP was set to 5 $cmH_2O$ in both group, in our study PEEP was increased from 12.1±2.5 cm $H_2O$ to 15.2±0.8 c $H_2O$ (P < 0.001)[12,39].

In conclusion this study suggests that further reduction of $V_T$ minimizes *tidal hyperinflation* and attenuates pulmonary inflammation in ARDS patients that, ventilated with the "*ARDSNet*" ventilation have a $P_{PLAT}$ ranging between 28 and 30 $cmH_2O$. Extracorporeal carbon dioxide removal effectively and safely managed the respiratory acidosis consequent to $V_T$ lower than 6 l/kg PBW and reestablished a normal arterial pH. This "proof of concept" study provides preliminary clinical evidence that extracorporeal lung support may integrate conventional care and allow the use of more protective ventilator settings. Additional clinical studies are required to further confirm these results.

# References

1.  Malhotra A: Low-tidal-volume ventilation in the acute respiratory distress syndrome. N Engl J Med 2007; 357: 1113-20

2.  ARDS Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342: 1301-8

3.  Terragni PP, Rosboch G, Tealdi A, Corno E, Menaldo E, Davini O, Gandini G, Herrmann P, Mascia L, Quintel M, Slutsky AS, Gattinoni L, Ranieri VM: Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. Am J Respir Crit Care Med 2007; 175: 160-6

4.  Hager DN, Krishnan JA, Hayden DL, Brower RG: Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. Am J Respir Crit Care Med 2005; 172: 1241-5

5.  Gattinoni L, Pesenti A, Mascheroni D, Marcolin R, Fumagalli R, Rossi F, Iapichino G, Romagnoli G, Uziel L, Agostoni A, Kolobow T, Damia G: Low-frequency positive-pressure ventilation with extracorporeal CO2 removal in severe acute respiratory failure. Jama 1986; 256: 881-6

6.  Morris AH, Wallace CJ, Menlove RL, Clemmer TP, Orme JF, Jr., Weaver LK, Dean NC, Thomas F, East TD, Pace NL, Suchyta MR, Beck E, Bombino M, Sitting DF, Bohm S, Hoffmann B, Becks H, Butler S, Pearl J, Rasmusson B: Randomized clinical trial of pressure-controlled inverse ratio ventilation and

extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 149: 295-305

7.      Deslauriers J, Awad JA: Is extracorporeal CO2 removal an option in the treatment of adult respiratory distress syndrome? Ann Thorac Surg 1997; 64: 1581-2

8.      Conrad SA, Rycus PT, Dalton H: Extracorporeal Life Support Registry Report 2004. Asaio J 2005; 51: 4-10

9.      Mielck F, Quintel M: Extracorporeal membrane oxygenation. Curr Opin Crit Care 2005; 11: 87-93

10.     Pesenti A, Rossi GP, Pelosi P, Brazzi L, Gattinoni L: Percutaneous extracorporeal CO2 removal in a patient with bullous emphysema with recurrent bilateral pneumothoraces and respiratory failure. Anesthesiology 1990; 72: 571-3

11.     Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-24

12.     Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351: 327-36

13.     Gattinoni L, Caironi P, Cressoni M, Chiumello D, Ranieri VM, Quintel M, Russo S, Patroniti N, Cornejo R, Bugedo G: Lung recruitment in patients with the acute respiratory distress syndrome. N Engl J Med 2006; 354: 1775-86

14.   Ramsay MA, Savege TM, Simpson BR, Goodwin R: Controlled sedation with alphaxalone-alphadolone. Br Med J 1974; 2: 656-9

15.   Decailliot F DA, Maggiore SM, Jonson B, Duvaldestin P, Brochard L Pressure-volume curves with and without muscle paralysis in acute respiratory distress syndrome. Intensive Care Med 2006; 32: 1322-8

16.   Conti G VV, Rocco M, DeBlasi RA, Lappa A, Bufi M, Antonelli M, Gasparetto A: Paralysis has no effect on chest wall and respiratory system mechanics of mechanically ventilated, sedated patients. Intensive Care Med 1995; 21: 808-12

17.   Grasso S, Mascia L, Del Turco M, Malacarne P, Giunta F, Brochard L, Slutsky AS, Marco Ranieri V: Effects of recruiting maneuvers in patients with acute respiratory distress syndrome ventilated with protective ventilatory strategy. Anesthesiology 2002; 96: 795-802

18.   Dembinski R, Hochhausen N, Terbeck S, Uhlig S, Dassow C, Schneider M, Schachtrupp A, Henzler D, Rossaint R, Kuhlen R: Pumpless extracorporeal lung assist for protective mechanical ventilation in experimental lung injury. Crit Care Med 2007; 35: 2359-66

19.   Livigni S, Maio M, Ferretti E, Longobardo A, Potenza R, Rivalta L, Selvaggi P, Vergano M, Bertolini G: Efficacy and safety of a low-flow veno-venous carbon dioxide removal device: Results of an experimental study in adult sheep. Crit Care 2006; 10: R151

20.   Lynch JE, Riley JB: Microemboli detection on extracorporeal bypass circuits. Perfusion 2008; 23: 23-32

21.   Shulman RI, Singer M, Rock J: Continuous renal replacement therapy. Keeping the circuit open: Lessons from the lab. Blood Purif 2002; 20: 275-81

22.   Jones NL: An obsession with CO2. Appl Physiol Nutr Metab 2008; 33: 641-50

23.   Le Gall JR LS, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. Jama 1993; 270: 2957-63

24.   Grasso S, Terragni P, Mascia L, Fanelli V, Quintel M, Herrmann P, Hedenstierna G, Slutsky AS, Ranieri VM: Airway pressure-time curve profile (stress index) detects tidal recruitment/hyperinflation in experimental acute lung injury. Crit Care Med 2004; 32: 1018-27

25.   Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, Bruno F, Slutsky AS: Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomized controlled trial. Jama 1999; 282: 54-61

26.   Laffey JG, O'Croinin D, McLoughlin P, Kavanagh BP: Permissive hypercapnia-- role in protective lung ventilatory strategies. Intensive Care Med 2004; 30: 347-56

27.   Kallet RH, Jasmer RM, Luce JM, Lin LH, Marks JD: The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). Am J Respir Crit Care Med 2000; 161: 1149-53

28.   Weber T, Tschernich H, Sitzwohl C, Ullrich R, Germann P, Zimpfer M, Sladen RN, Huemer G: Tromethamine buffer modifies the depressant effect of permissive hypercapnia on myocardial contractility in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 162: 1361-5

29. Morris AH: Extracorporeal support and patient outcome: Credible causality remains elusive. Crit Care Med 2006; 34: 1551-2

30. Lewandowski K, Rossaint R, Pappert D, Gerlach H, Slama KJ, Weidemann H, Frey DJ, Hoffmann O, Keske U, Falke KJ: High survival rate in 122 ARDS patients managed according to a clinical algorithm including extracorporeal membrane oxygenation. Intensive Care Med 1997; 23: 819-35

31. Bartlett RH, Roloff DW, Custer JR, Younger JG, Hirschl RB: Extracorporeal life support: The University of Michigan experience. Jama 2000; 283: 904-8

32. Grasso S, Stripoli T, De Michele M, Bruno F, Moschetta M, Angelelli G, Munno I, Ruggiero V, Anaclerio R, Cafarelli A, Driessen B, Fiore T: ARDSnet ventilatory protocol and alveolar hyperinflation: Role of positive end-expiratory pressure. Am J Respir Crit Care Med 2007; 176: 761-7

33. Reng M, Philipp A, Kaiser M, Pfeifer M, Gruene S, Schoelmerich J: Pumpless extracorporeal lung assist and adult respiratory distress syndrome. Lancet 2000; 356: 219-20

34. Bein T, Weber F, Philipp A, Prasser C, Pfeifer M, Schmid FX, Butz B, Birnbaum D, Taeger K, Schlitt HJ: A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. Crit Care Med 2006; 34: 1372-7

35. Gattinoni L, Caironi P, Carlesso E: How to ventilate patients with acute lung injury and acute respiratory distress syndrome. Curr Opin Crit Care 2005; 11: 69-76

36. Pesenti A, Pelizzola A, Mascheroni D, Uziel L, Pirovano E, Fox U, Gattinoni L, Kolobow T: Low frequency positive pressure ventilation with extracorporeal $CO_2$

removal (LEPPV-ECCO2R) in acute respiratory failure (ARF): Technique. Trans Am Soc Artif Intern Organs 1981; 27: 263-6

37.    Gattinoni L, Mascheroni D, Torresin A, Marcolin R, Fumagalli R, Vesconi S, Rossi GP, Rossi F, Baglioni S, Bassi F, Nastri G, Pesenti A: Morphological response to positive end expiratory pressure in acute respiratory failure. Computerized tomography study. Intensive Care Med 1986; 12: 137-42

38.    Ronco C: Continuous renal replacement therapies in the treatment of acute renal failure in intensive care patients. Part 2. Clinical indications and prescription. Nephrol Dial Transplant 1994; 9 Suppl 4: 201-9

39.    Corbridge TC, Wood LD, Crawford GP, Chudoba MJ, Yanos J, Sznajder JI: Adverse effects of large tidal volume and low PEEP in canine acid aspiration. Am Rev Respir Dis 1990; 142: 311-5